As cell therapy programs progress, downstream formulation and fill-finish processes must support evolving manufacturing requirements while maintaining the level of control and quality expected for high-value therapies.
In a recent evaluation, Cellipont Bioservices assessed the Xiogenix ARES™ X20+ across small- and large-scale cell therapy manufacturing workflows, with manual filling included for comparison. The study reflects the industry’s move toward more innovative, controlled downstream processing, with ARES™ X20+ providing a closed, automated approach designed to reduce unnecessary product handling and manual intervention.
Key Findings from the Evaluation
- Post-thaw viability:0% with automated filling vs. 79.7% with manual filling
- Fill variability:9% CV with automated filling vs. 12.0% with manual filling
- 1 mL vial fills:2% mean fill accuracy*
- Large-scale bag fills:9–101.1% of target fill volume
*1 mL vial-fill results exclude two identified outlier vials.
The ARES™ X20+ is designed with the flexibility to support a range of manufacturing scales, with programmable fill volumes from 0.5 mL to 1,000 mL, source volumes from 30 mL to 50 L, and compatibility with both vial and bag workflows.
What This Means for the Future of Fill & Finish
These findings provide a closer look at how closed, automated fill-finish can support the control, consistency, and process confidence required in increasingly sophisticated cell therapy manufacturing environments.
As the industry continues to advance, this study adds valuable data to the evolving conversation around downstream manufacturing, helping teams explore how automation can support repeatable, scalable fill-finish workflows across clinical and commercial applications.
